Search - tctmd.com

Displaying 461 - 480 of 551

Sort: Relevancy | Date

News Daily News

Warfarin Offers Poor Protection Against Radial Occlusion After Transradial Angiography

November 26, 2013

Presentation TCT 2013

Management of a Patient on Novel Oral Anticoagulants Needing Urgent Cath

Presenter: Michael Ezekowitz

October 31, 2013

Presentation TCT 2013

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Presenter: Kurt Huber

October 31, 2013

Presentation TCT 2013

Pulmonary Embolism: When to Use Lytics, When to Use Novel Oral Anticoagulants

Presenter: Ori Ben-Yehuda

October 31, 2013

Presentation TCT 2013

Novel Oral Anticoagulants for Atrial Fibrillation: What You Need to Know to Use Them Safely

Presenter: Jonathan Halperin

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Presenter: Pascal Vranckx

October 31, 2013

News Conference News TCT 2013

Debate Leaves Little Doubt of LAA Closure Efficacy in the Prevention of Stroke in AF Patients

October 30, 2013

News Conference News TCT 2013

Understanding Differences Among New Oral Anticoagulants Should Increase Compliance

October 28, 2013

News Conference News TCT 2013

Experts Discuss Efficacy, Safety of Watchman Device

October 28, 2013

Presentation TCT 2013

Who Should Receive the New Chronic Oral Anticoagulants? Which One?

Presenter: Christopher Granger

October 27, 2013

News Daily News

Oral Direct Thrombin Inhibitors Linked to Increased MI Risk

L.A. McKeown

October 04, 2013

News Daily News

No Administrar Aspirina Pre-PCI es Causa Habitual de Complicaciones

Caitlin E. Cox

October 04, 2013

News Daily News

Los Inhibidores Orales Directos de la Trombina se asocian a un Mayor Riesgo de IM

L.A. McKeown

October 04, 2013

News Daily News

Failure to Give Pre-PCI Aspirin Not Infrequent Cause of Complications

Caitlin E. Cox

October 04, 2013

News Conference News ESC 2013

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

September 09, 2013

News Conference News ESC 2013

New Alternatives Match Efficacy to Warfarin in High-Risk Subgroups

Caitlin E. Cox

September 03, 2013

News Conference News ESC 2013

Novel Anticoagulant Edoxaban Surpasses Warfarin Across Spectrum of VTE Patients

Caitlin E. Cox

September 02, 2013

News Daily News

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

August 30, 2013

News Daily News

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

August 30, 2013

News Daily News

Nonvalvular A-fib Patients More Likely to Remain on Dabigatran Than Warfarin

Jason Kahn

August 12, 2013

Advertisement

Warfarin Offers Poor Protection Against Radial Occlusion After Transradial Angiography

Management of a Patient on Novel Oral Anticoagulants Needing Urgent Cath

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Pulmonary Embolism: When to Use Lytics, When to Use Novel Oral Anticoagulants

Novel Oral Anticoagulants for Atrial Fibrillation: What You Need to Know to Use Them Safely

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Debate Leaves Little Doubt of LAA Closure Efficacy in the Prevention of Stroke in AF Patients

Understanding Differences Among New Oral Anticoagulants Should Increase Compliance

Experts Discuss Efficacy, Safety of Watchman Device

Who Should Receive the New Chronic Oral Anticoagulants? Which One?

Oral Direct Thrombin Inhibitors Linked to Increased MI Risk

No Administrar Aspirina Pre-PCI es Causa Habitual de Complicaciones

Los Inhibidores Orales Directos de la Trombina se asocian a un Mayor Riesgo de IM

Failure to Give Pre-PCI Aspirin Not Infrequent Cause of Complications

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

New Alternatives Match Efficacy to Warfarin in High-Risk Subgroups

Novel Anticoagulant Edoxaban Surpasses Warfarin Across Spectrum of VTE Patients

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

Nonvalvular A-fib Patients More Likely to Remain on Dabigatran Than Warfarin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content